evipedia.ai
← Back

Kisspeptin-10 for Health & Longevity

Created on 10/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Kisspeptin-10, an injectable peptide that switches on the brain's reproductive signal, is used to raise one's own sex-hormone output. In men, brief or intermittent doses reliably raise testosterone, but steady exposure loses the effect; in women, response varies with hormone levels and cycle timing. It clears in about four minutes, has not been studied beyond twelve days in people, has no approved product, and anti-doping authorities prohibit it. (Full Review)

Protocol

Research bolus dose
0.3-1.0 µg/kg intravenously
Near-maximal LH pulse in men; 3 µg/kg gave a smaller response than 1 µg/kg
Competing approach, intermittent subcutaneous
150 nmol/h for 8 hours daily
Over 12 days; the only schedule shown to sustain gonadotropin output
Split versus single dosing
Repeated hourly boluses
Sustained pulsatile LH output over 10 hours; matches the pathway better than one daily dose
Time to effect
Time to effect
Minutes
LH peaks around 30 minutes after a bolus; any testosterone change follows over hours
Time to loss of effect
24 hours to 5 days
Continuous exposure weakens the LH response within 24 hours; gonadotropins back to inactive-control levels by 5 days
No withdrawal syndrome described
Back to baseline within minutes
Trials reported no rebound or withdrawal effects on stopping; the axis returns as the peptide clears

Benefits

Contraindications
  • Pregnant or possibly pregnant individuals
  • People with hormone-sensitive cancer, including prostate and breast cancer
  • People with established atherosclerotic disease
  • Anyone who has not completed puberty
    •
Key Interactions
  • Combined oral contraceptives (ethinylestradiol plus progestogen): LH response abolished
  • Estradiol replacement: LH pulse amplitude rose with estradiol level in postmenopausal women
  • Neurokinin 3 receptor antagonists (MLE4901): LH response preserved, FSH response increased
  • GnRH (gonadorelin): additive gonadotropin surge
  • Opioid receptor antagonists (naltrexone): raised LH pulse amplitude
    •
Theoretical (inferred from mechanism)
  • Exogenous testosterone and anabolic androgens: blunted or abolished response
  • GnRH agonists and antagonists (leuprolide, degarelix): loss of the intended gonadotropin rise
  • Other axis stimulants (clomiphene): additive rise in LH and testosterone
  • Dopamine antagonists that raise prolactin (antipsychotics): blunted, though not absent, response
  • Antihypertensives and vasodilators (amlodipine, nitrates): opposing effect on vascular tone
  • Over-the-counter agents that raise prolactin or oppose androgens (cimetidine): blunted gonadotropin response
  • Androgen-precursor supplements (DHEA): enlarged hormone swing at first, blunted response later
    •

Risk & Side Effects

  • High: Loss of gonadotropin response with sustained exposure
    •
  • Medium:
  • Low: Vasoconstriction and atherosclerotic plaque progression; anxiety or mood disturbance
    •
  • Speculative: Immunogenicity and peptide-related impurities; degraded or mislabelled product from unregulated supply; receptor signalling in tumour cells; vessel-lining cell senescence and impaired vessel growth; inhibition of placenta-forming cell invasion in early pregnancy
    •

Monitoring

Marker Target Why
Luteinizing hormone (LH) 1.8-8.6 IU/L (men), 2.4-12.6 IU/L (women, follicular) Direct readout of the pathway
Follicle-stimulating hormone (FSH) 1.5-12.4 IU/L (men), 3.5-12.5 IU/L (women, follicular) Expected to change; rises alongside LH
Total testosterone (men) 264-916 ng/dL Expected to change; a fall below baseline detects a lost response
Estradiol (women) 19-144 pg/mL (follicular), 64-357 pg/mL (periovulatory), under 10-28 pg/mL (postmenopausal) Expected to change; sets the expected size of the response
Haematocrit 38.3-48.6% (men), 35.5-44.9% (women) Safety check on red cell mass
Prostate-specific antigen (men over 40) No established target; track change from the individual's own baseline Safety check on the prostate during any androgen rise

Cadence: Baseline before any exposure; hormone panel at 2 weeks and 4 weeks, then every 3 months while exposure continues; haematocrit and prostate-specific antigen every 6 months

Qualitative Assessment

  • Libido and spontaneous sexual interest
  • Mood and anxiety
  • Sleep quality
  • Energy and training recovery
  • Injection-site reactions and any flushing or headache around dosing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.